Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 283 (planned)
- Started
- Oct 1, 2025
- Main results expected
- Jan 18, 2029
- Fully finished
- Jan 18, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs)
Measured over: From Day 1 up to approximately 3 years
Module 1 and 2: Part A: Number of participants with Dose Limiting Toxicities (DLTs)
Measured over: From Day 1 up to end of DLT period (approximately 21 days)
Module 1: Parts B and C and Module 2: Part B: Percentage of participants with Prostate-Specific Antigen (PSA) 50 response rate
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07181161 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC